Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

(2014) Douglas Dieterich et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Basel Cocktail for Simultaneous Phenotyping of Human Cytochrome P450 Isoforms in Plasma, Saliva and Dried Blood Spots

(2013) Massimiliano Donzelli et al.   CLINICAL PHARMACOKINETICS

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial

(2013) Mark S. Sulkowski et al.   HEPATOLOGY

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

(2013) Mark S. Sulkowski et al.   HEPATOLOGY

The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects

(2013) Thomas N. Kakuda et al.   JOURNAL OF CLINICAL PHARMACOLOGY

1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

(2013) P. Ferenci et al.   JOURNAL OF HEPATOLOGY

Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection

(2013) Shuhei Nishiguchi et al.   LIVER INTERNATIONAL

Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions

(2012) David Burger et al.   JOURNAL OF HEPATOLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

(2010) P. W. White et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir

(2010) J B Dumond et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

(2010) Michael P. Manns et al.   JOURNAL OF HEPATOLOGY

Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction

(2009) O. A. Fahmi et al.   DRUG METABOLISM AND DISPOSITION